



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/510,066	10/04/2004	Craig W. Lindsley	21072YP	5610

210 7590 10/13/2006

MERCK AND CO., INC
P O BOX 2000
RAHWAY, NJ 07065-0907

EXAMINER

BERNHARDT, EMILY B

ART UNIT	PAPER NUMBER
----------	--------------

1624

DATE MAILED: 10/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/510,066

Applicant(s)

LINDSLEY ET AL.

Examiner

Emily Bernhardt

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-14,20 and 21 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-14,20 and 21 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 12/20/04 & 4/24/06.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____.

The abstract of the disclosure is objected to because it does not convey a structural makeup. Correction is required. See MPEP § 608.01(b).

Claims 1-5,8,10-12,14 and 20-21 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

1. The nature of “optional” substituents for benzyl in R_b is not set forth in the claims nor is it seen in the specification as far as the examiner can determine.
2. Claims 10-11 are unclear as to intended scope. Such claim language reciting inhibitory activity is generally used to denote a causative factor in determining the process by which a particular disease occurs. Determining whether a given disease responds or not to inhibition of “one or more of the isoforms of Akt” involves much experimentation since a negative response from one patient does not mean the drug isn't useful as no drug has 100% effectiveness. Thus what “success rate” determines if a particular compound is effective and how many patients (and dosage regimens) need to be tested? The test for determining compliance with 35 USC 112, par.two is whether applicants have clearly defined “their” invention not what may be discovered by future research as this type of claim language clearly requires.

3. When the variable “w” is a bond and the R¹ variable is absent then variable “x”

is left with a dangling valence since it is no longer doubly bonded but only singly bonded. Examples show only "H" when "x" is "N". Note that "x" can also be "CH" which is also open-ended when this situation arises.

Clarification/amendment is needed.

Claims 1-5, 8, 10-4 and 20-21 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

1). Specification is not adequately enabled by way of working examples for the scope of bis-phenyl compounds claimed which are not even limited to a particular azine core but can include up to 6 N atoms in the tricyclic ring system which can have a variety of heterocyclic groups including fused rings and substituted derivatives thereof at all R variables. It is stated in the specification on p.86 that: "Compounds of the instant invention described were tested in the assay...". Said compounds are always fused quinoxalines with outer ring mainly a 5-membered diazole or triazole and when 6-membered is a benzo. Substituents thereon are oxo when 5-membered or are unsubstituted. When NR₅R₆ forms a ring it is always a saturated monocyclic ring having 1N and when substituted with

hetero rings is of the scope recited in claim 4 without further substitution thereon as well as one example of a purinyl. The second phenyl ring is unsubstituted. Thus, there is no reasonable basis for assuming that the myriad of remaining compounds embraced by the claims will all share the same physiological properties since they are so structurally dissimilar as to be chemically non-equivalent and there is no basis in the prior art for assuming the same. Note *In re Surrey* 151 USPQ 724 regarding sufficiency of disclosure for a Markush group. Also see MPEP 2164.03 for enablement requirements in cases directed to structure-sensitive arts such as the pharmaceutical art. Also note the criteria for enablement as set out in *In re Wands* cited in MPEP 2164.01(a), August 2000 edition, which includes factors such as:

1) Breadth of the claims- the claims cover compounds easily in the millions as pointed out above;

2) Level of unpredictability in the art- the invention is pharmaceutical in nature as the compounds are taught to act as inhibitors of Akt activity of which there are many forms. It is well established that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved” and physiological activity is generally considered to be unpredictable. See *In re Fisher* 166 USPQ 18;

3) Direction or guidance- as stated above only a small portion of instant scope has been tested as stated on p.86;

4) State of the prior art- The compounds are 2,3-diphenyl fused quinoxalines as well as fused quinolines having a myriad of rings at the outer ring. While some of such compounds have been described in a commonly assigned publication (applied below) the publication at best tests an even smaller portion of instant compounds;

5) Working examples- No actual test data has been presented only an upper limit is reported on p.86 and thus no clear evaluation of which functional groups at various positions out of the many claimed might affect potency to a large or small degree.

In view of the above considerations, this rejection is being applied.

2.) Method claims 10-13 and 20-21 are also rejected herein for the following reasons. Treating cancer (much less preventing recited in claim 20) is not enabled solely on the reliance of assay testing for inhibition of the activity of one or more isoforms of AKT. While AKT inhibition may be implicated in the development of certain cancers as discussed in the references, Nakatani and Bellacosa, there is no basis in the prior art at the time of applicants' effective filing that any AKT inhibitor much less as a class are known to treat all cancers. Note Hanada, a more

recent publication, evidences that research in this area is in the preliminary stages.

Note the criteria for enablement as set out in *In re Wands* cited in MPEP

2164.01(a), August 2000 edition, which includes factors such as:

1) Level of unpredictability in the art- The invention is pharmaceutical in nature involving inhibition of one or more kinases of which many types currently exist with differing biological functions as discussed in Nakatani and Bellasco. It is well established that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved” and physiological activity is generally considered to be unpredictable. See *In re Fisher* 166 USPQ 18. ;

2) Direction or guidance- The amount of guidance presented in the specification as to which compounds are sufficiently active to be useful for the claimed uses is nonexistent;

3) Working examples- The test data presented is for an assay testing which is not art-recognized as being reasonably predictive of *in vivo* efficacy. Thus in the absence of animal studies and in the absence of any correlation between studies conducted **in vitro** and the diseases to be treated, there is no sufficient evidence to support the claimed uses;

4) Level of skill in the art- The area directed to PKT inhibition is very experimental with no indication of any such drug(s) actually known to treat one or

more cancers and thus the level of skill is low. If applicants disagree they need to provide references showing at the time of applicants' filing date one or more cancers described herein would be reasonably treatable in man, the intended host with Akt inhibitors.

Where the assertion of utility is unusual, difficult to treat or speculative, the examiner has authority to require evidence that tests relied on are reasonably predictive of in vivo efficacy by those skilled in the art. See for example, In re Ruskin 148 USPQ 221; Ex parte Jovanovics 211 USPQ 907. Note MPEP. 2164.05(a).

In view of the above considerations, this rejection is being applied.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-14 and 20-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Barnett (WO'473, provided by applicants). The WO publication describes several different cores including instant core having the same type of substitution thereon. See pages 51-55, 75-77 and 104,142-143 which include

species within the instant scope which are particularly claimed in claims 6 as well as 7. Said compounds are taught for treating cancers via Akt inhibition either alone or with additional active ingredients as set forth on page 13 and many following pages. Barnett is applied as of its US provisional filing date of 4/8/02 since pertinent subject matter described above is present in the earlier case.

It is recognized applicants' are claiming benefit of 2 earlier provisional cases under 35 USC 119(e). Benefit cannot be accorded since species in claims 6 and 7 are not entirely described in earliest provisional and the generic claims are otherwise not in compliance with 35 USC 112, par. one as required in the MPEP 706.02, section V, part (D), Rev. 2 May 2004.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an

invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-14 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims of copending Application No. 10/510,068. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the copending case embrace instant subject matter as the same species described in the above 102(e) rejection are covered by the claims of 10/510,068 which is the US equivalent of WO'473. The claims are directed to treating cancer. As this is the only use known for the instant compounds, the compound/composition claims are also rejected herein as being drawn to the same invention. Note *In re Boylan* 147 USPQ 370. It is recognized that the case has not yet been examined and may otherwise be subject to a restriction requirement. If this case is otherwise in condition for allowance, the provisional rejection will be dropped. Applicants should inform the examiner handling the copending case that the instant case exists.


This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP Chapter 2300). Commonly assigned 10/510,068, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Bernhardt whose telephone number is 571-272-0664.

If attempts to reach the examiner by telephone are unsuccessful, the acting supervisor for AU 1624, James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.


Emily Bernhardt
Primary Examiner
Art Unit 1624